Immunocore (IMCR)
(Delayed Data from NSDQ)
$38.91 USD
-0.71 (-1.79%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $39.00 +0.09 (0.23%) 7:58 PM ET
4-Sell of 5 4
F Value B Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
IMCR 38.91 -0.71(-1.79%)
Will IMCR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IMCR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IMCR
Sarepta's (SRPT) DMD Drug sBLA Gets FDA's Priority Tag, Stock Up
Zacks Industry Outlook Highlights Sarepta, Exelixis, Immunocore, Editas and Puma Biotechnology
IMCR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zoetis' (ZTS) Q4 Earnings Miss Expectations, Sales Beat
5 Biotech Stocks to Consider for Your Portfolio in 2024
Immunovant (IMVT) Up 3% as Q3 Earnings Top, Pipeline in Focus
Other News for IMCR
Immunocore to report second quarter 2024 financial results and host call on August 8, 2024
Warning: IMCR is at high risk of performing badly
The Galien Foundation Announces 2024 International Prix Galien and Prix Galien Italy Award Winners
Yellowstone Biosciences launches with #16.5 million to pioneer soluble bispecific TCR-based therapies for cancer
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma